These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 7381862)

  • 41. The debrisoquine/sparteine oxidation polymorphism: evidence of genetic heterogeneity among Ghanaians.
    Woolhouse NM
    Prog Clin Biol Res; 1986; 214():189-206. PubMed ID: 3725761
    [No Abstract]   [Full Text] [Related]  

  • 42. Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquine.
    Bertilsson L; Dengler HJ; Eichelbaum M; Schulz HU
    Eur J Clin Pharmacol; 1980 Feb; 17(2):153-5. PubMed ID: 7371707
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine.
    Speirs CJ; Murray S; Boobis AR; Seddon CE; Davies DS
    Br J Clin Pharmacol; 1986 Dec; 22(6):739-43. PubMed ID: 3567021
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Polymorphism of carbon oxidation of drugs and clinical implications.
    Sloan TP; Mahgoub A; Lancaster R; Idle JR; Smith RL
    Br Med J; 1978 Sep; 2(6138):655-7. PubMed ID: 151576
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Altered distribution of debrisoquine oxidation phenotypes in patients with systemic lupus erythematosus.
    Baer AN; McAllister CB; Wilkinson GR; Woosley RL; Pincus T
    Arthritis Rheum; 1986 Jul; 29(7):843-50. PubMed ID: 3741500
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Polymorphic drug oxidation in humans.
    Eichelbaum M
    Fed Proc; 1984 May; 43(8):2298-302. PubMed ID: 6714436
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations.
    Nakamura K; Goto F; Ray WA; McAllister CB; Jacqz E; Wilkinson GR; Branch RA
    Clin Pharmacol Ther; 1985 Oct; 38(4):402-8. PubMed ID: 4042523
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Drug hydroxylation disorders (debrisoquin type) in a random sample of the Swiss population].
    Dick B; Küpfer A; Molnàr J; Braunschweig S; Preisig R
    Schweiz Med Wochenschr; 1982 Jul; 112(30):1061-7. PubMed ID: 7123181
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Non-correlation between debrisoquine and metoprolol polymorphisms in the Venda.
    Sommers DK; Moncrieff J; Avenant J
    Hum Toxicol; 1989 Sep; 8(5):365-8. PubMed ID: 2807305
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Polymorphic oxidation of debrisoquine in lung cancer patients.
    Benítez J; Ladero JM; Jara C; Carrillo JA; Cobaleda J; Llerena A; Vargas E; Muñoz JJ
    Eur J Cancer; 1991; 27(2):158-61. PubMed ID: 1827280
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The metabolism of mexiletine in relation to the debrisoquine/sparteine-type polymorphism of drug oxidation.
    Broly F; Vandamme N; Libersa C; Lhermitte M
    Br J Clin Pharmacol; 1991 Oct; 32(4):459-66. PubMed ID: 1958440
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The genetic polymorphism of debrisoquine/sparteine metabolism-molecular mechanisms.
    Meyer UA; Skoda RC; Zanger UM
    Pharmacol Ther; 1990; 46(2):297-308. PubMed ID: 2181495
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Bufuralol metabolism in human liver: a sensitive probe for the debrisoquine-type polymorphism of drug oxidation.
    Minder EI; Meier PJ; Müller HK; Minder C; Meyer UA
    Eur J Clin Invest; 1984 Jun; 14(3):184-9. PubMed ID: 6147254
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Extensive metabolizers of debrisoquine become poor metabolizers during quinidine treatment.
    Brøsen K; Gram LF; Haghfelt T; Bertilsson L
    Pharmacol Toxicol; 1987 Apr; 60(4):312-4. PubMed ID: 3588528
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Defective metabolism of metoprolol in poor hydroxylators of debrisoquine.
    Lennard MS; Silas JH; Freestone S; Trevethick J
    Br J Clin Pharmacol; 1982 Aug; 14(2):301-3. PubMed ID: 6125207
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Xenobiotic and endobiotic inhibitors of cytochrome P-450dbl function, the target of the debrisoquine/sparteine type polymorphism.
    Fonne-Pfister R; Meyer UA
    Biochem Pharmacol; 1988 Oct; 37(20):3829-35. PubMed ID: 2903741
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Polymorphism of debrisoquine oxidation in New Zealand Caucasians.
    Wanwimolruk S; Denton JR; Ferry DG; Beasley M; Broughton JR
    Eur J Clin Pharmacol; 1992; 42(3):349-50. PubMed ID: 1577057
    [No Abstract]   [Full Text] [Related]  

  • 58. In-vivo and in-vitro dextromethorphan metabolism in SD and DA rat. An animal model of the debrisoquine-type polymorphic oxidation in man.
    Zysset T; Zeugin T; Küpfer A
    Biochem Pharmacol; 1988 Aug; 37(16):3155-60. PubMed ID: 3401246
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Debrisoquine oxidation phenotype in psychiatric patients.
    Benítez J; Piñas B; García MA; Martínez C; Llerena A; Cobaleda J
    Psychopharmacol Ser; 1989; 7():206-10. PubMed ID: 2594729
    [No Abstract]   [Full Text] [Related]  

  • 60. Metoprolol and debrisoquin metabolism in Nigerians: lack of evidence for polymorphic oxidation.
    Iyun AO; Lennard MS; Tucker GT; Woods HF
    Clin Pharmacol Ther; 1986 Oct; 40(4):387-94. PubMed ID: 3757401
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.